New imaging study aims to unmask why some prostate cancer metastases resist treatment

NCT ID NCT07302763

Recruiting now Knowledge-focused Sponsor: Frederic Pouliot Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will use special PET scans with two different tracers to see how each individual prostate cancer metastasis responds to therapy. Researchers want to understand why some metastases shrink while others grow during the same treatment. The goal is to better characterize resistance patterns and guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PET tracers (FDG and PSMA)
What this could lead to: If successful, this could help doctors identify which metastases are resistant to therapy, potentially guiding more personalized treatment decisions.
What could go wrong: This is an early-stage imaging study with only 45 participants, so results may not apply to all patients. It does not test a new treatment, only how to better monitor existing ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MCRPC (METASTATIC CASTRATION-RESISTANT PROSTATE CANCER)

Contacts and locations

Locations

CHU de Québec-Université Laval
RECRUITING

Québec, Quebec, G1J1Z4, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.